ERYPAR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Erypar, and when can generic versions of Erypar launch?
Erypar is a drug marketed by Parke Davis and Warner Chilcott and is included in two NDAs.
The generic ingredient in ERYPAR is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ERYPAR?
- What are the global sales for ERYPAR?
- What is Average Wholesale Price for ERYPAR?
Summary for ERYPAR
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 26 |
| Patent Applications: | 1 |
| DailyMed Link: | ERYPAR at DailyMed |
US Patents and Regulatory Information for ERYPAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parke Davis | ERYPAR | erythromycin stearate | TABLET;ORAL | 062032-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Parke Davis | ERYPAR | erythromycin stearate | TABLET;ORAL | 062032-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Warner Chilcott | ERYPAR | erythromycin stearate | TABLET;ORAL | 062322-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
